NVS-CECR2-1 (NVS-1) is a potent and selective inhibitor of CECR2 (cat eye syndrome chromosome region, candidate 2) gene. CECR2 is duplicated in the human disorder cat eye syndrome, which includes defects of the eye, heart, anus, kidney, skeleton, face, and may include mild mental deficiency. CECR2 is involved in neurulation, the folding process that results in the transformation of the neural plate into the neural tube, and is also thought to play a role in DNA damage response. NVS-CECR2-1 (NVS-1) binds to CECR2 with high affinity. It has an IC50 value of 47 nM in Alpha screen and a KD of 80 nM in ITC. NVS-CECR2-1 showed no cross reactivity in a BRD panel of 48 targets or any major activity in kinase, protease and receptor panels. For full characterization details, please visit the NVS-CECR2-1 probe summary
on the Structural Genomics Consortium (SGC) website.
To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc